New directions in antihistamine research

Bibliography

• COOPER DG, YOUNG RC, DURANT GJ, GANELLIN CR: Histamine receptors. In: Comprehensive Medicinal Chem-istry. Hansch C, Taylor JB (Eds.), Pergamon Press, London (1990323–421. A general review of histamine receptors.
   Google Scholar
• CASEY AF: Chemistry and structure activity relation-ships of synthetic antihistamines. In: Histamine Hand antihistaminic: chemistry, metabolism, and physiological and pharmacological actions. Rocha E, Silva M (Eds.), Springer Verlag, Berlin (1978) 18\(Part 2):179.
   Google Scholar
• ARRANG J-M, GARBARG M, SCHWARTZ J-C: Auto-inhibi-tion of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature (1983) 302:832–837.
   PubMed Web of Science ®Google Scholar
• LEURS R, VOLLINGA RC, TIMMERMAN H: The medicinalchemistry and therapeutic potentials of ligands of the histamine H3 receptor. In: Progress in Drug Research. Jucker E (Ed.), Birkhauser Verlag, Basel (1995):107–165.
   Google Scholar
• FISCHER RG: Clinical use and selection of the antihista-mines. Drug Topics (1991) (Special Supplement):1–10.
   Google Scholar
• TARNASKY PR, VAN ARSDAL PP: Antihistamine therapy in allergic rhinitis. J. Family Pract (1990) 30 (1):71–80.
   PubMedGoogle Scholar
• Annual report top 100 drugs. Med. Ad. News (1996):48–51.
   Google Scholar
• RIMMER SJ, CHURCH MK: The pharmacology and mecha-nisms of action of histamine Hi antagonists. Clin. Exp. Allergy (1990) 20 (Suppl. 2):3–17.
   Google Scholar
• Ebastine: a novel Hi receptor antagonist. Drugs Today (1992) 28(Suppl. B):1–79.
   Google Scholar
• WISEMAN LR, FAULDS D: Ebastine. Drugs (1996) 51(2):260–277.
   PubMed Web of Science ®Google Scholar
• FOGNER A, BECHTEL WD, KUHN FJ, MIERAU J: In vitroand in vivo studies of the non-sedating antihistamine epinastine. Arzneim.-Forsch/DrugResearch (1988) 38:1446–1453.
   PubMedGoogle Scholar
• WALTHER G, DANIEL H, BECHTEL WD, BRANDT K: Newtetracyclic guanidine derivatives with Hi antihistaminic properties. Arzneim.-Forsch/Drug Research (1990) 40:440–445.
   PubMed Web of Science ®Google Scholar
• MEALY N, NGO J, CASTAUER J: Mizolastine. Drugs Future (1996) 21 (8):799–804.
   Google Scholar
• MATSUDA M, SAKASHITA M, MIZUKI Y etal: Comparative pharmokinetics of the histamine Hi receptor antago-nist ebastine and its active metabolite carebastine in rats, guinea-pigs, dogs and monkeys. Arzneim.-Forsch/Drug Research (1994) 44:55–59.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI T, HASHIZUME T, MATSUDA M et al.: Phar-mokinetics of the Hi receptor antagonists ebastine and its active metabolite carebastine in healthy subjects. Arzneim.-Forsch/Drug Research (1994) 44:59–63.
   PubMed Web of Science ®Google Scholar
• MACCONNELL TJ, STANNERS AJ: Toursades de Pointes complicating treatment with terfenadine. Br. Med. J (1991) 302:469.
   Google Scholar
• MONAHAN BP, FERGUSON CL, KILLEAV ES eta].: Torsades de Pointes occurring in association with terfenadine use. J. Amer. Med. Assoc. (1990) 264:2788–2790.
   Google Scholar
• HONIG PK, WORTHAM DC, ZAMANI KI, CONNER DP, CANTILENA LR: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of ter-fenadine with concomitant administration of erythro-mycin. Clin. Pharm. Ther. (1992) 3:231–238.
   Google Scholar
• HEY JA, DEL PRADO M, CUSS FM et al.: Antihistamine activity, central nervous system and cardovascular profiles of histamine Hi antagonists: comparative stud-ies with loratadine, terfenadine and sedating antihista-mines in guinea-pigs. Clin. Exp. Allergy (1995) 25:974–984.
   PubMed Web of Science ®Google Scholar
• WILEY JF, GELBER ML, HENRETIG FM et al: Cardiotoxic effects of astemizole overdose in children. J. Pediatr. (1992) 120:799–802.
   PubMed Web of Science ®Google Scholar
• GARTEIZ DA, HOOK RH, WALKER BJ, OKERHOLM RA: Pharmacokinetics and biotransformation studies of terfenadine in man. Arzneim.-Forsch/Drug Research (1982) 32:1185–1190.
   PubMed Web of Science ®Google Scholar
• Histamine and antihistamine. In: Drug Evaluations. Ben-net DR (Ed.), American Medical Association (1994) 3:2.1–2.15.
   Google Scholar
• GRAUL AS, CASTARER J: Fexofenadine hydrochloride. Drugs Future (1996) 21(101017–1021.
   Google Scholar
• ZHANG MQ, WADA Y, SATO F TIMMERMAN H: (Piperid-inylalkoxy)chromones: novel antihistamines with ad-ditional antagonist activity against leukotriene D4. J. Med. Chem. (1995) 38:2472–2477.
   PubMedGoogle Scholar
• AYSCOUGH A, WHITTAKER M: Platelet-activating factor receptor antagonists. Exp. Opin. Ther. Patents (1995) 5:653–672.
   Google Scholar
• KOLTAI M, BRAQUET PG: Platelet-activating factor an-tagonists. Clin. Rev. Allergy (1994) 12:361–380.
   PubMedGoogle Scholar
• SUMMERS JB, ALBERT DH: Platelet-activating factor an-tagonists. In: Advances in Pharmacology August JT, Anders MW, Murad F, Coyle J (Eds.), Academic Press, San Diego (1995):67–168.
   Google Scholar
• GUINOT P: Clinical experience with platelet-activating factor antagonists. Clin. Rev. Allergy (1994) 12:397–417.
   PubMedGoogle Scholar
• PIWINSKI JJ, WONG JK, GREEN MJ et al.: Dual antagonists of platelet activating factor and histamine. Identifica-tion of structural requirements for dual activity of N-acy1-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b ]pyridin-11-ylidene)piperidines. J. Med. Chem. (1991) 34:457–461.
   Google Scholar
• CARCELLER E, MERLOS M, GIRAL M et al.: [(3-Pyridylal-kyDp iper idyll de ne] benzocycl ohe pt apyri dine deriva-tives as dual antagonists of PAF and histamine. J. Med. Chem. (1994) 37: 2697–2703.
   PubMed Web of Science ®Google Scholar
• CORTIJO J, FARRE AJ, GUTIERREZ B, MORCILLO EJ: Anti-asthma activity of the novel antihistamine E-4716 in guinea-pigs in viva Methods Find. Exp. Clin. Pharmacol (1996) 18:465–473.
   Google Scholar
• GUTIERREZ B, DORDAL A, FORT M, GALICIA J, FARRE AJ: Effects of E-4716, a new antihistamine with anti-allergic properties, on chemical mediators induction of immu-nologic reactions. Methods Find. Exp. Clin. Pharmacol (1996) 18:397–406.
   PubMedGoogle Scholar
• PARIS D, COTTIN M, DEMONCHAUX P et al: Synthesis, structure-activity relationships, and pharmacological evaluation of pyr rolo[3,2,1-ij] quinoline derivatives: po-tent histamine and platelet-activating factor antago-nism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma. J. Med. Chem. (1995) 38:669–685.
   Google Scholar
• KUDLACZ EM, SHATZER SA, KNIPPENBERG RW et al.: In vitro and in vivo characterisation of MDL 105,212A, a nonpeptide NKi/NK2 tachykinin recptor antagonists. J. Pharmacol Exp. Ther. (1996) 277:840–851.
   PubMed Web of Science ®Google Scholar
• IFFLAND J, WOLF C, ELZ S, SCHUNACK W: Synthesis and in vitro activities of combined histamine Hi/H2 recep-tor antagonists. 14th International Medical Chemistry Sym-posium. The Netherlands, (Sept. 1996), Abstract P-2.18.
   Google Scholar
• WOLF C, SCHUNACK W: Synthesis and pharmacology of combined histamine Hi/H2 receptor antagonists con-taining diphenhydramine and cyproheptadine deriva-tives. Arch. Pharm. Med. Chem. (1996) 329:87–94.
   PubMedGoogle Scholar
• MARRION MERREL DOW, W09606094 (1996).
   Google Scholar